Floatz logo

Cetuximab

mCRC

Shanghai Henlius Biotechmonoclonal_antibodyPhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the mCRC cohort.

Asset / SponsorPhaseRating
Eloxatin
Shanghai Henlius Biotech
Phase 2B
FLUOROURACILUM
Shanghai Henlius Biotech
Phase 2B
Calcium folinate pentahydrate
Shanghai Henlius Biotech
Phase 2B
Pelareorep
Oncolytics Biotech
Phase 2CCC
Irinotecan
Oncolytics Biotech
Phase 2CCC

View all 20 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →